文献速递银屑病与炎症性皮肤病

Socrodeucitinib治疗中重度斑块状银屑病的随机2期试验

A randomized phase 2 trial of socrodeucitinib in moderate-to-severe plaque psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-07-28

这项2期双盲安慰剂对照试验将125例中重度斑块状银屑病患者按1:1:1随机分配至Socrodeucitinib 6 mg、12 mg或安慰剂口服每日一次治疗12周。结果显示12周时6 mg和12 mg组PASI 75应答率分别为28.6%和72.1%,均显著高于安慰剂的7.5%;12 mg组PASI 90和PASI 100应答率分别为46.5%和11.6%。药物总体安全性良好,最常见不良事件为上呼吸道感染。

要点

  • Socrodeucitinib 12 mg组12周PASI 75达72.1%,显著优于安慰剂7.5%。
  • 12 mg组PASI 90和PASI 100分别为46.5%和11.6%。
  • 总体安全性良好,最常见不良事件为上呼吸道感染。

核心结论

  • Socrodeucitinib在中重度斑块状银屑病患者中较安慰剂显著改善皮损清除,并表现出良好的安全性和耐受性。

研究设计与样本

  • 2期双盲安慰剂对照试验,125例患者按1:1:1随机接受Socrodeucitinib 6 mg、12 mg或安慰剂口服每日一次治疗12周。
  • 主要终点为第12周PASI评分较基线改善≥75%的患者比例。

主要发现

  • 第12周PASI 75应答率:6 mg组28.6%、12 mg组72.1%、安慰剂组7.5%(p<0.05和p<0.001)。
  • 12 mg组PASI 90应答率46.5%(p<0.001),PASI 100应答率11.6%(p<0.05)。
  • sPGA 0或1应答率:6 mg组33.3%、12 mg组65.1%、安慰剂组10%(p<0.05和p<0.001)。
  • 最常见不良事件为上呼吸道感染,呈一定剂量依赖性;多数治疗相关不良事件为轻中度,严重不良事件不常见。

关键数值与推荐

  • PASI 75:6 mg组28.6%、12 mg组72.1% vs 安慰剂7.5%(p<0.05和p<0.001)。
  • PASI 90(12 mg组)46.5%(p<0.001);PASI 100(12 mg组)11.6%(p<0.05)。
  • sPGA 0或1:6 mg组33.3%、12 mg组65.1% vs 安慰剂10%(p<0.05和p<0.001)。

临床怎么用

  • Socrodeucitinib 12 mg每日一次治疗12周可显著改善中重度斑块状银屑病皮损,且安全性良好,支持进一步开展更长疗程和更大样本研究。

局限性

  • 研究为2期试验,样本量125例,疗程仅12周,需更长疗程和更大规模试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis. OBJECTIVES: To evaluate the efficacy and safety of socrodeucitinib in patients with moderate-to-severe plaque psoriasis. METHODS: In this phase 2, double-blind, placebo-controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6 mg, 12 mg or placebo orally, once daily, for 12 weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12. RESULTS: At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6 mg, 72.1% at 12 mg vs. 7.5% for placebo, p < 0.05 and p < 0.001, respectively). At the 12 mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 (p < 0.001) and 11.6% achieving PASI 100 (p < 0.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6 mg and 65.1% at 12 mg versus 10% for placebo (p < 0.05 and p < 0.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment-related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters. CONCLUSIONS: Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate-to-severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer-duration and larger trials.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Han L, Geng S, Ding Y, et al. A randomized phase 2 trial of socrodeucitinib in moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2026. PMID: 42517728. doi:10.1111/jdv.70643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。